Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)
ID: 356067Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances," aimed at supporting research into the biological mechanisms by which sex hormones affect the outcomes of comorbid HIV and substance use disorders (SUDs). This initiative encourages applicants to explore molecular pathways that could serve as therapeutic targets, with a strong emphasis on including diverse perspectives through a required Plan for Enhancing Diverse Perspectives (PEDP). Grants of up to $400,000 per year are available under the R01 grant mechanism, with applications due by March 13, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-007.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a funding opportunity aimed at advancing research on the interactions between sex hormones, HIV, and substance use disorders (SUDs). This initiative, titled "Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances," encourages investigators to explore the biological mechanisms by which sex hormones affect the outcomes of comorbid HIV and drug addiction. Grants of up to $400,000 per year are available under the R01 grant mechanism, with application deadlines set for February 12, 2025. The initiative emphasizes the inclusion of diverse perspectives in research, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Eligible applicants include a wide range of entities, from higher education institutions to non-profits and government agencies. The funding aims to uncover molecular pathways that can be targeted for therapeutic interventions addressing the complex relationship between HIV and substance abuse, ultimately improving treatment strategies for these comorbid conditions.
    Similar Opportunities
    Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances," aimed at supporting studies that explore the biological mechanisms linking sex hormones, HIV, and substance use disorders (SUD). This initiative encourages exploratory research that elucidates how sex hormones affect HIV replication and addiction behaviors, particularly in populations affected by both HIV and drug addiction, while requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The funding opportunity allows for grant applications of up to $275,000 over a two-year period, with a submission deadline of March 13, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-008.html.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use" (RFA-DA-25-069). This initiative aims to support research that elucidates the mechanisms of inflammasome activation related to neurocognitive disorders in individuals affected by HIV and substance use disorders (SUDs), focusing on identifying molecular markers and understanding the inflammatory responses triggered by these conditions. The program is significant for developing new therapeutic tools that could enhance clinical outcomes for affected populations. Up to four grants, totaling $2 million, will be awarded, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for detailed application instructions.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use," aimed at advancing the understanding of the interplay between neuroimmune networks and the effects of HIV and substance use disorders (SUD). This R01 Clinical Trial Not Allowed grant seeks applications that explore neuroimmune interactions, therapeutic targets, and modulatory tools, with a focus on examining the molecular mechanisms and regulatory pathways influenced by substance use in relation to HIV pathogenesis. The opportunity is significant for addressing HIV-related neurological issues exacerbated by substance abuse, with a total funding of up to $2 million projected for FY 2025 to support up to six projects. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD," aimed at researching the interplay between mitochondrial function, aging, HIV infection, and substance use disorders (SUD). This initiative seeks to uncover protective and pathogenic mechanisms that could lead to the development of targeted therapies to improve health outcomes for individuals aging with HIV and addiction issues. Approximately $3 million in funding is available, with anticipated awards ranging from three to six grants, and a Plan for Enhancing Diverse Perspectives (PEDP) is required from applicants. The application process will commence in February 2025, with a submission deadline of March 10, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-009.html.